Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
INDGN

Indegene Share Price

 

 

Indegene live price: ₹491.75. It opened at ₹498 vs previous close ₹493; intraday high/low: ₹498/₹482. The 50 & 200 DMA stand at ₹477.51/₹514.30.

Indegene Performance

  • Today's Low
  • ₹482
  • Today's High
  • ₹498
  • 52 Week Low
  • ₹414
  • 52 Week High
  • ₹633
  • Open Price₹498
  • Previous Close₹493
  • Volume304,897
  • 50 DMA₹477.51
  • 100 DMA₹490.22
  • 200 DMA₹514.30

Indegene Chart

Investment Returns

  • Over 1 Month + 16.12%
  • Over 3 Month + 3.68%
  • Over 6 Month -9.99%
  • Over 1 Year -14.67%

Smart Investing Starts Here Start SIP with Indegene for Steady Growth!

Invest Now

Indegene Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 27
  • PEG Ratio
  • 1.9
  • Market Cap Cr
  • 11,835
  • P/B Ratio
  • 4
  • Average True Range
  • 16.94
  • EPS
  • 18.22
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 6.36
  • RSI
  • 56.92
  • MFI
  • 61.46

Indegene Financials

Indegene Technicals

EMA & SMA

Current Price
₹491.75
-1.2 (-0.24%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹480.16
  • 50 Day
  • ₹477.51
  • 100 Day
  • ₹490.22
  • 200 Day
  • ₹514.30

Resistance and Support

490.4 Pivot Speed
  • R3 515.75
  • R2 506.85
  • R1 499.30
  • S1 482.85
  • S2 473.95
  • S3 466.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indegene is a global healthcare solutions company providing commercial, medical, and digital transformation services to life sciences companies. It helps pharmaceutical, biotech, and healthcare organizations enhance patient outcomes through data-driven strategies and innovative technology solutions.

Indegene Ltd has an operating revenue of Rs. 3,262.70 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 19% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Indegene Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-04-29 Audited Results & Final Dividend
2026-01-29 Quarterly Results & ESOP
2025-10-30 Quarterly Results
2025-07-31 Quarterly Results
2025-04-28 Audited Results & Final Dividend
Date Purpose Remarks
2025-06-13 FINAL Rs.2.00 per share(100%)Final Dividend
View Indegene Dividend History Arrow

Indegene F&O

Indegene Shareholding Pattern

0%
4.7%
0.01%
10.27%
12.56%
72.46%

Indegene FAQs

Indegene share price is ₹491 As on 24 April, 2026 | 19:22

The Market Cap of Indegene is ₹11834.6 Cr As on 24 April, 2026 | 19:22

The P/E ratio of Indegene is 27 As on 24 April, 2026 | 19:22

The PB ratio of Indegene is 4 As on 24 April, 2026 | 19:22

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23